{"entity":{"id":"nct05987956","kind":"trial","name":"Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms","aka":[],"tldr":"A phase 2/3 trial of Alectinib in non-small-cell lung cancer, run by Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair, active and no longer recruiting.","summary":"Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms is a phase 2/3 interventional study registered as NCT05987956 by Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair, with 600 participants enrolled, started 2026-03-18 and due to reach its primary completion in 2026-11-18. Interventions recorded: ALECENSA - alectinib hydrochloride capsule.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05987956","url":"https://clinicaltrials.gov/study/NCT05987956"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["alectinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05987956","phase":"2/3","setting":"Explore the Relationship Between Single Nucleotide Polymorphisms and Alectinib Response and Toxicity in Patients With Non-Small Cell Lung Cancer.","sponsor":"Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair","enrolled":600,"outcomes":[]},"route":"/trials/nct05987956/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"alectinib","kind":"drug","name":"Alectinib","route":"/drugs/alectinib/"}]}}